Litigation
Jan. 28, 2017
Longrunning antitrust case recovers $399 million for class members
The last defendant in an antitrust drug case has settled for $225 million, bringing the total recovery to nearly $400 million.
Daily Journal Staff Writer
Putting an end to the 17-year-long prescription drug class action that netted nearly $400 million for class members, the remaining defendant in an antitrust lawsuit has agreed to pay $225 million to settle allegations it participated in a scheme that monopolized the price of the antibacterial drug Cipro.
Plaintiffs' attorneys said the agreement, announced Wednesday with Barr Laboratories Inc...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In